Home > Publications database > Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial. > print

001     303378
005     20250810021959.0
024 7 _ |a 10.1136/jitc-2025-011874
|2 doi
024 7 _ |a pmid:40759442
|2 pmid
024 7 _ |a altmetric:180043204
|2 altmetric
037 _ _ |a DKFZ-2025-01627
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Eichhorn, Martin E
|b 0
245 _ _ |a Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754484280_17116
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The phase II NEOMUN trial was conducted to investigate the therapeutic effect of preoperative programmed death receptor-1 inhibitor pembrolizumab for treating non-small cell lung cancer (NSCLC). Herein, we report the final efficacy, safety, and long-term survival results.Patients with resectable stage II/IIIA NSCLC were included. Two cycles of pembrolizumab (200 mg intravenously once every 3 weeks) were administered before surgery. The primary objectives were to assess the feasibility and safety of neoadjuvant treatment and evaluate antitumor activity. We analyzed the clinical parameters and pathologic, radiological, and metabolic tumor response data.29 patients with NSCLC were enrolled. NSCLC histology revealed adenocarcinoma and squamous cell carcinoma in 24 and in 5 patients, respectively. 93.1% of patients were treated with two therapy cycles. 73 adverse events were reported, of which 18 were treatment-related. Complete tumor resection rate was 100%. Major (≤10% vital tumor cells) and complete pathologic response rates were 24.1% and 13.8%, respectively. Tumor response increased with higher programmed death-ligand 1 tumor proportion scores (TPS) and high pretherapeutic tumor mutational burden (≥10 mut./Mb). The metabolic response, quantified non-invasively using positron emission tomography/CT, predicted the pathologic tumor response. The disease-free survival was 75.9% at 24 and 36 months, and the overall survival was 82.7% at 24 and 36 months.Neoadjuvant immunotherapy with pembrolizumab appears safe and feasible and is associated with a remarkable major pathologic response rate. Preoperative TPS, change in maximal standardized uptake value during the induction phase, and high mutational burden might be suitable clinical parameters for predicting pathologic response in surgical candidates.NCT0319746.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Biomarker
|2 Other
650 _ 7 |a Immune Checkpoint Inhibitor
|2 Other
650 _ 7 |a Major pathologic response - MPR
|2 Other
650 _ 7 |a Neoadjuvant
|2 Other
650 _ 7 |a Non-Small Cell Lung Cancer
|2 Other
650 _ 7 |a pembrolizumab
|0 DPT0O3T46P
|2 NLM Chemicals
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a Programmed Cell Death 1 Receptor
|2 NLM Chemicals
650 _ 7 |a Immune Checkpoint Inhibitors
|2 NLM Chemicals
650 _ 7 |a Antineoplastic Agents, Immunological
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: therapeutic use
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: pharmacology
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: drug therapy
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: pathology
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: mortality
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Lung Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Lung Neoplasms: pathology
|2 MeSH
650 _ 2 |a Neoadjuvant Therapy: methods
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Programmed Cell Death 1 Receptor: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Immunotherapy: methods
|2 MeSH
650 _ 2 |a Immune Checkpoint Inhibitors: therapeutic use
|2 MeSH
650 _ 2 |a Immune Checkpoint Inhibitors: pharmacology
|2 MeSH
650 _ 2 |a Antineoplastic Agents, Immunological: therapeutic use
|2 MeSH
650 _ 2 |a Antineoplastic Agents, Immunological: pharmacology
|2 MeSH
700 1 _ |a Niedermaier, Benedikt
|b 1
700 1 _ |a Charoentong, Pornpimol
|0 P:(DE-He78)8dde8d3920dc06c59314abdb4ac7d2e8
|b 2
|u dkfz
700 1 _ |a Klotz, Laura V
|b 3
700 1 _ |a Baum, Philip
|b 4
700 1 _ |a Griffo, Raffaella
|b 5
700 1 _ |a Allgäuer, Michael
|b 6
700 1 _ |a Stenzinger, Albrecht
|b 7
700 1 _ |a Bischoff, Helge
|b 8
700 1 _ |a Schneider, Marc A
|b 9
700 1 _ |a Christopoulos, Petros
|b 10
700 1 _ |a Haberkorn, Uwe
|b 11
700 1 _ |a Heußel, Claus-Peter
|b 12
700 1 _ |a Savai, Rajkumar
|0 0000-0003-1538-2091
|b 13
700 1 _ |a Roberti, Maria Paula
|0 P:(DE-He78)72e6f8462f1b903eef99df71d9d8817b
|b 14
|u dkfz
700 1 _ |a Zoernig, Inka
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Jäger, Dirk
|0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
|b 16
|u dkfz
700 1 _ |a Herth, Felix
|b 17
700 1 _ |a Thomas, Michael
|b 18
700 1 _ |a Winter, Hauke
|b 19
700 1 _ |a Eichhorn, Florian
|b 20
773 _ _ |a 10.1136/jitc-2025-011874
|g Vol. 13, no. 8, p. e011874 -
|0 PERI:(DE-600)2719863-7
|n 8
|p e011874
|t Journal for ImmunoTherapy of Cancer
|v 13
|y 2025
|x 2051-1426
909 C O |o oai:inrepo02.dkfz.de:303378
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)8dde8d3920dc06c59314abdb4ac7d2e8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)72e6f8462f1b903eef99df71d9d8817b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J IMMUNOTHER CANCER : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-24T13:16:43Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-24T13:16:43Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-24T13:16:43Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J IMMUNOTHER CANCER : 2022
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l Angewandte Tumor-Immunität
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21